Apremilast for moderate hidradenitis suppurativa: Results of a randomized controlled trial

Effective anti-inflammatory treatments for hidradenitis suppurativa (HS) are limited. To evaluate the efficacy and short-term safety of apremilast in patients with moderate HS. A total of 20 patients with moderate HS were randomized in a 3:1 ratio to receive blinded treatment with apremilast, 30 mg...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of the American Academy of Dermatology 2019-01, Vol.80 (1), p.80-88
Hauptverfasser:	Vossen, Allard R.J.V., van Doorn, Martijn B.A., van der Zee, Hessel H., Prens, Errol P.
Format:	Artikel
Sprache:	eng
Schlagworte:	acne inversa Adult Anti-Inflammatory Agents, Non-Steroidal - therapeutic use Double-Blind Method efficacy Female Hidradenitis Suppurativa - drug therapy Humans Male PDE4 phosphodiesterase 4 inhibitor randomized controlled trial safety Severity of Illness Index Thalidomide - analogs & derivatives Thalidomide - therapeutic use tolerability treatment Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!